On 28 Jan 2020, Agile Therapeutics, Inc. stock identified change of 1020.00% away from 52-week low price and recently located move of 9.50% off 52-week high price. AGRX stock has been recorded 63.78% away from 50 day moving average and 147.51% away from 200 day moving average. Moving closer, we can see that shares have been trading 35.71% off 20-day moving average.
Agile Therapeutics, Inc. (AGRX), a women’s healthcare company, recently reported the appointment of Kimberly Whelan as Vice President of Market Access. Ms. Whelan has over 35 years of experience in the healthcare industry working in finance, sales, marketing, business development, and managed markets.
Ms. Whelan is responsible for overseeing the development and execution of Agile’s market access strategy in preparation for the potential commercialization of the company’s lead product candidate, Twirla® (AG200-15), which has a PDUFA goal date of February 16, 2020.
At the same time, Agile has filled two additional positions to further strengthen its finance and marketing capabilities. Charles S. Grass, CMA, has been named Senior Director, Finance and Matthew Riley has been named Product Manager.
AGRX’s shares are at 243.86% for the quarter and driving a 361.72% return over the course of the past year and is now at 56.80% since this point in 2018. The average volatility for the week at 11.59% and for month was at 9.03%. The Healthcare sector company, Agile Therapeutics, Inc. noticed change of 14.96% to $3.92 along volume of 5510868 shares in recent session compared to an average volume of 6264.14K.